Terumo Corporation
IFRS Financial Results for the First Quarter of theFiscal Year Ending March 31, 2021

－1－

－ 2－

4. Consolidated Financial Statements① Consolidated Statement of Financial Position（Unit: Millions of yen）
As ofJune 30, 2020

As ofMarch 31, 2020
AssetsCurrent assets
Cash and cash equivalents

166,898

212,014

Trade and other receivables

131,728

117,416

Other current financial assets

397

228

147,147

161,815

Current tax assets

1,745

1,696

Other current assets

12,68913,930Total current assets

460,607507,102

Property, plant and equipment264,407

269,654

Goodwill and intangible assets

461,506

456,204

Inventories

Non-current assets

Investments accounted for using
the equity method
Other non-current financial assets

5,275

5,094

17,733

16,214

Deferred tax assets

27,30728,078Other non-current assets

4,517

4,291

Total non-current assets

780,748779,538

1,241,355

1,286,641

Total assets－ 3－

（Unit: Millions of yen）
As ofJune 30, 2020

As ofMarch 31, 2020
Liabilities and Equity
Liabilities
Current liabilities
Trade and other payables

88,044

78,149Bonds and borrowings

50,32450,000

Other current financial liabilities

6,144

6,695

Current tax liabilities

11,681

15,705395

358

Other current liabilities

55,25647,151

Total current liabilities

211,845

198,060

Bonds and borrowings

195,870

251,405

Other non-current financial liabilities

31,802

33,083

Deferred tax liabilities

20,36019,008

Defined benefit liabilities

18,456

19,39592

92

Other non-current liabilities

8,043

7,594

Total non-current liabilities

274,626

330,579

486,472

528,639

Share capital

38,716

38,716

Capital surplus

51,85851,891

Treasury shares(14,103)(10,371)Retained earnings

705,765

710,561

Other components of equity(27,423)(32,835)

Provisions

Non-current liabilities

Provisions

Total liabilities
EquityTotal equity attributable to ownersof the parent
Non-controlling interests

754,813

Total equity
Total liabilities and equity－ 4－757,96369

37

754,883

758,001

1,241,355

1,286,641

② Consolidated Statement of Profit or Loss
For the three months ended
June 30, 2019
152,526
67,35685,16956,365
1,151
787
29,168486
767（Unit: Millions of yen）
For the three months ended
June 30, 2020
131,298
62,42468,873
51,255844
388
18,073
352
589

(43)

49

28,844
6,092
22,751

17,885
3,913
13,971Attributable to:
Owners of the parent
Non-controlling interests
Total profit for the period

22,791(39)
22,751

14,002(31)
13,971

Earnings per share
Basic earnings per share (yen)Diluted earnings per share (yen)

30.67
30.15

18.57
18.50

Revenue
Cost of sales
Gross profit
Selling, general and administrative expenses
Other income
Other expenses
Operating profit
Finance incomeFinance costs
Share of profit (loss) of investments
accounted for using the equity method
Profit before tax
Income tax expenses
Profit for the period－ 5－

③ Consolidated Statement of Comprehensive Income

For the three months ended
June 30, 201922,751（Unit: Millions of yen）
For the three months ended
June 30, 2020
13,971

920

420

920

420

(20,853)(5,061)

(22)

433

(80)

233

(20,955)(4,395)(20,034)(3,974)

2,717

9,997

Owners of the parent

2,751

10,028Non-controlling interests

(33)

(31)

2,717

9,997

Profit for the period
Other comprehensive income
Items that will not be reclassified to profit or loss
Changes in financial assets measured at fair value
through other comprehensive income
Total items that will not be reclassified to profit orloss
Items that are or may be reclassified subsequently
to profit or loss
Exchange differences on translation of foreign
operations
Cash flow hedges
Cost of hedging
Total items that are or may be reclassified
subsequently to profit or loss
Total other comprehensive income (loss)
for the period
Total comprehensive income for the period
Attributable toTotal comprehensive income for the period(Note)

Items in the above statement are net of tax.

－ 6－④ Consolidated Statements of Changes in Equity（Unit: Millions of yen）
Share
capitalBalance as of April 1, 2019

38,716Equity attributable to the owners of the parent
Other
CapitalTreasury
Retainedcomponents
surplussharesearnings
of equity

52,029(32,381)646,223

Profit for the period

22,791

Total comprehensive income
Acquisition of treasury shares(1)

Disposal of treasury shares

18

(5)

Dividends

78

698,113

22,791(39)

22,751(20,040)(20,040)

5(20,034)(20,040)

2,751

(33)

2,717

(1)

(1)

00

(10,029)(10,029)(13)(10,029)

Change in shares of subsidiaries due
to capital increase
Conversion of convertible bonds

Total

698,034

22,791Other comprehensive income

Total transactions with the owners of
the parent
Balance as of June 30, 2019

(6,553)

Noncontrollinginterests

Total

53

38,716

53

(3)

446

(6)

436

436

(3)

464

(10,041)(13)(9,594)53(9,540)52,025(31,917)

658,973(26,606)

691,19198

691,290（Unit: Millions of yen）
SharecapitalBalance as of April 1, 2020

38,716Equity attributable to the owners of the parent
Other
CapitalTreasury
Retainedcomponents
surplussharesearnings
of equity

51,858(14,103)705,765

Profit for the period(27,423)

14,002

Total comprehensive income
Acquisition of treasury shares(0)

Disposal of treasury shares

430Dividends

69754,883

14,002(31)

13,971(3,973)(3,973)(0)(3,974)(3,973)

10,028

(31)

9,997

(43)

(10,531)

(0)

(0)

00

(10,531)(10,531)

50

50

3,602

3,602
(6,879)Transfer from other components ofequity to retained earnings
Share-based payments

50

Conversion of convertible bonds

(17)

3,689

(69)

33

3,731

(9,206)(1,437)(6,879)51,891(10,371)

710,561(32,835)

757,963

Total transactions with the owners ofthe parent
Balance as of June 30, 2020

1,393

38,716

－ 7－

Total

754,813

14,002Other comprehensive income

Noncontrollinginterests

Total(1,393)37758,001

⑤ Segment informatition▪ Reportable segment information

Revenue and operating results of the reportable segments of the Group are described below.
▪ Changes in name of reportable segment

The segment previously named “Blood Management Company” was changed to “Blood and Cell Technologies
Company” from the fiscal year ended March 31, 2020. This change in name does not affect the segment information.
The name of reportable segment for the fiscal year ended June 30, 2019 was also revised to “Blood and CellTechnologies Company”.
For the first quarter of the fiscal year ended June 30, 2019
（Unit: Millions of yen）
Reportable Segments

Revenue
Revenue from sales toexternal customers
Segment Profit(Adjusted operatingprofit)(Adjustment item）
Amortization of intangible
assets acquired throughbusiness combinations
Non-recurring profit orloss

Adjustments(Note）

Amountrecorded on
consolidated
financialstatements

152,47254

152,526

2,630

32,3981,550

33,949(2,074)(3,862)(150)(4,013)

Cardiacand
VascularCompany

GeneralHospitalCompany

Blood and
Cell
Technologies
Company

88,50239,75624,212

24,5275,241(1,787)

Total

(767)

Operating profit

29,168Finance income

486

Finance costs
Share of profit/(loss) ofinvestment accounted forusing the equity method(767)

Profit before tax

28,844(43)(Note) Amounts in ‘Adjustments’ are as follows:(1) ¥54 million adjustment to revenue from sales to external customers is mainly proceeds from temporary
staffing that is not attributable to reportable segments.
(2) ¥1,550 million adjustment to segment profit consists of ¥899 million for “inventories” and ¥651 million for“others”.

－ 8－For the first quarter of the fiscal year ended June 30, 2020
（Unit: Millions of yen）
Reportable Segments

Revenue
Revenue from sales toexternal customers
Segment Profit(Adjusted operatingprofit)(Adjustment item）
Amortization of intangible
assets acquired throughbusiness combinationsNon-recurring profit orloss

Adjustments(Note）

Amountrecorded on
consolidated
financialstatements

131,232

65

131,298

3,886

21,463

222

21,685(2,031)(3,765)269(3,496)

Cardiacand
VascularCompanyGeneral
HospitalCompany

Blood and
Cell
Technologies
Company

67,31539,18324,733

12,4055,171(1,733)

Total

(116)

Operating profit

18,073Finance income

352

Finance costs
Share of profit/(loss) ofinvestment accounted forusing the equity method(589)

Profit before tax

17,88549(Note) Amounts in ‘Adjustments’ are as follows:(1) ¥65 million adjustment to revenue from sales to external customers is mainly proceeds from temporary
staffing that is not attributable to reportable segments.
(2) ¥222 million adjustment to segment profit consists of ¥197 million for “inventories” and ¥25 million for“others”.

－ 9－